ARQT Arcutis Biotherapeutics, Inc. - Common stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 5, 2026
$25,16
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$19,3052 haftanın en düşüğü
$31,7752 haftanın en yükseği
Piyasa Değeri (MRQ)
$3.16B
P/E (TTM)
114.4
Hisse Başına Kâr (TTM)
$0.22
Gelir (TTM)
$464M
rozetleriniz
52 Haftlık Aralık
$19–$32
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$37
P/E
114.4
ROE
15.9%
Net Kâr Marjı
6.1%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
ARQT Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$25.16
Piyasa Değeri (MRQ)
$3.16B
P/E (TTM)
114.4
Hisse Başına Kâr (TTM)
$0.22
Gelir (TTM)
$464M
ROE (TTM)
15.9%
D/E Borç/Özsermaye (MRQ)
0.5
52 Haftlık Aralık
$19–$32
ARQT Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$376M2020-12-31 → 2025-12-31
Hisse Başına Kâr$-0.132019-12-31 → 2025-12-31
Serbest Nakit Akışı$-6M2020-12-31 → 2025-12-31
Net kar marjı6.1%2023-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | ARQT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 114.45Y ort. ≈-48.8 | ≈-48.8 | 27.9 | Aşırı değerli | |
| F/S (TTM) | 6.85Y ort. ≈7.7 | ≈7.7 | 11.9 | Düşük değerli | |
| F/D (MRQ) | 14.35Y ort. ≈10.9 | ≈10.9 | 4.9 | Aşırı değerli | |
| EV / EBITDA | -259.25Y ort. ≈-104.4 | ≈-104.4 | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | 80.75Y ort. ≈-194.5 | ≈-194.5 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 80.45Y ort. ≈-217.5 | ≈-217.5 | · | · | |
| EV / Revenue (EV / Gelir) | 8.45Y ort. ≈8.5 | ≈8.5 | · | · | |
| EV / FCF | -502.25Y ort. ≈-198.2 | ≈-198.2 | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 15.35Y ort. ≈8.7 | ≈8.7 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | ARQT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 7.4%5Y ort. ≈-157.7% | ≈-157.7% | 12.5% | Aynı seviyede | |
| EBITDA Margin (FAVÖK Marjı) | -3.2%5Y ort. ≈-157.7% | ≈-157.7% | 12.5% | Aynı seviyede | |
| Net Kâr Marjı (TTM) | 6.1%5Y ort. ≈-171.8% | ≈-171.8% | 10.2% | Aynı seviyede | |
| ROA (TTM) | 6.8%5Y ort. ≈-37.0% | ≈-37.0% | -13.8% | En üst düzey | |
| ROE (TTM) | 15.9%5Y ort. ≈-162.1% | ≈-162.1% | -10.7% | Aynı seviyede |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | ARQT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.55Y ort. ≈1.2 | ≈1.2 | · | · | |
| Cari Oran (MRQ) | 2.95Y ort. ≈4.8 | ≈4.8 | 4.6 | Düşük likidite | |
| Quick Ratio (Cari Oran) | 1.55Y ort. ≈1.9 | ≈1.9 | 4.1 | Düşük likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.55Y ort. ≈1.2 | ≈1.2 | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | ARQT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 91.3%5Y ort. ≈612.7% | ≈612.7% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 367.3% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | ARQT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 1.05Y ort. ≈0.6 | ≈0.6 | 0.4 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 2.05Y ort. ≈1.3 | ≈1.3 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 3.45Y ort. ≈3.6 | ≈3.6 | 8.4 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$1.1M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
56.7%
Sonraki Rapor
Eki 26, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 4, 2026 | $0.11 | $0.04 | 150.6% |
| 31 Mart 2026 | $-0.09 | $-0.08 | -7.4% | |
| 31 Aralık 2025 | $0.13 | $0.12 | 12.4% | |
| 30 Eylül 2025 | $0.06 | $-0.10 | 158.9% | |
| 30 Haziran 2025 | $-0.13 | $-0.16 | 19.4% | |
| 31 Mart 2025 | $-0.20 | $-0.21 | 6.6% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $376M | $197M | $60M | $4M | $0 | $0 | |
| Cost of Revenue | $37M | $19M | $5M | $754.0K | $0 | · | |
| R&D Expense | $77M | $76M | $111M | $182M | $146M | $115M | |
| SG&A Expense | $275M | $229M | $185M | $122M | $61M | $21M | |
| Operating Expenses | $388M | $325M | $301M | $305M | $207M | $137M | |
| Operating Income | $-12M | $-128M | $-241M | $-302M | $-207M | $-137M | |
| Interest Expense | · | · | $30M | $16M | $0 | $0 | |
| Other Non-op | $443.0K | $47.0K | $-731.0K | $6M | $173.0K | $967.0K | |
| Income Tax | $1M | $647.0K | $3M | $0 | $0 | $0 | |
| Net Income | $-16M | $-140M | $-262M | $-311M | $-206M | $-136M | |
| EPS (Basic) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 | |
| EPS (Diluted) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 | |
| Shares (Basic) | 127,234,000 | 120,958,000 | 69,305,000 | 55,032,265 | 49,405,575 | 35,668,152 | |
| Shares (Diluted) | 127,234,000 | 120,958,000 | 69,305,000 | 55,032,265 | 49,405,575 | 35,668,152 | |
| EBITDA | $-12M | $-128M | $-241M | · | · | $-137M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $71M | $88M | $54M | $96M | $65M | |
| Receivables | $146M | $73M | $26M | $8M | $0 | · | |
| Inventory | $23M | $15M | $13M | $8M | $0 | · | |
| Prepaid Expense | $21M | $20M | $19M | $11M | $14M | $7M | |
| Current Assets | $411M | $336M | $330M | $437M | $403M | $293M | |
| PP&E (Net) | $1M | $1M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $4M | $4M | $3M | $3M | $3M | $2M | |
| Accum. Depreciation | $3M | $3M | $2M | $1M | $532.0K | $78.0K | |
| Intangibles | $15M | $9M | $6M | $7M | $0 | · | |
| Other Non-current Assets | $1M | $596.0K | $596.0K | $78.0K | $78.0K | $78.0K | |
| Total Assets | $433M | $349M | $341M | $449M | $408M | $298M | |
| Accounts Payable | $13M | $14M | $12M | $9M | $7M | $7M | |
| Accrued Liabilities | $116M | $67M | $34M | $28M | $26M | $15M | |
| Current Liabilities | $130M | $81M | $47M | $38M | $33M | $23M | |
| Capital Leases | $5M | $3M | $3M | $4M | $5M | $5M | |
| Other Non-current Liabilities | $431.0K | $570.0K | $849.0K | $0 | $25.0K | $82.0K | |
| Total Liabilities | $243M | $191M | $253M | $240M | $110M | $28M | |
| Long-term Debt | $109M | $107M | $202M | $198M | $72M | $0 | |
| Total Debt | $109M | $107M | $202M | · | · | · | |
| Common Stock | $12.0K | $12.0K | $9.0K | $6.0K | $5.0K | $4.0K | |
| Paid-in Capital | $1.33B | $1.28B | $1.07B | $930M | $706M | $473M | |
| Retained Earnings | $-1.14B | $-1.12B | $-982M | $-720M | $-408M | $-202M | |
| AOCI | $-44.0K | $-7.0K | $4.0K | $-1M | $-255.0K | $-2.0K | |
| Stockholders' Equity | $189M | $158M | $89M | $210M | $298M | $271M | |
| Liabilities + Equity | $433M | $349M | $341M | $449M | $408M | $298M | |
| Shares Outstanding | 123,333,000 | 117,848,033 | 96,787,343 | 61,037,403 | 50,255,614 | 43,338,438 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $40M | $42M | $39M | $33M | $24M | $8M | |
| Deferred Tax | $54.0K | $-152.0K | $0 | $0 | $0 | · | |
| Amort. of Intangibles | $5M | $2M | $750.0K | $312.0K | $0 | $0 | |
| Operating Cash Flow | $-6M | $-112M | $-247M | $-258M | $-175M | $-113M | |
| CapEx | $686.0K | $143.0K | $428.0K | $333.0K | $995.0K | $321.0K | |
| Investing Cash Flow | $-30M | $29M | $180M | $-87M | $-76M | $-182M | |
| Debt Issued | · | $0 | $0 | $125M | $74M | $0 | |
| Net Debt Issued | $0 | $-100M | $0 | · | · | · | |
| Stock Issued | $0 | $162M | $0 | $162M | $207M | $128M | |
| Net Stock Activity | $0 | $162M | $0 | · | · | $128M | |
| Financing Cash Flow | $7M | $66M | $101M | $302M | $282M | $298M | |
| Net Change in Cash | $-29M | $-17M | $34M | $-43M | $31M | $3M | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | |
| Free Cash Flow | $-6M | $-112M | $-247M | · | · | $-113M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -3.2% | -65.3% | -404.5% | · | · | · | |
| Net Margin | -4.3% | -71.2% | -439.8% | · | · | · | |
| EBITDA Margin | -3.2% | -65.3% | -404.5% | · | · | · | |
| ROA | -4.1% | -40.6% | -66.3% | · | · | -67.0% | |
| ROE | -9.8% | -89.1% | -387.2% | · | · | -61.2% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 4.1 | 7.1 | · | · | 13.0 | |
| Quick Ratio | 1.5 | 1.8 | 2.4 | · | · | 2.9 | |
| Debt / Equity | 0.6 | 0.7 | 2.3 | · | · | · | |
| LT Debt / Equity | 0.6 | 0.7 | 2.3 | · | · | · | |
| Interest Coverage | · | · | -8.1 | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.0 | 0.6 | 0.2 | · | · | · | |
| Inventory Turnover | 2.0 | 1.4 | 0.5 | · | · | · | |
| Receivables Turnover | 3.4 | 4.0 | 3.5 | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.54 | $1.34 | $0.92 | · | · | $6.24 | |
| Revenue / Share | $2.96 | $1.62 | $0.86 | · | · | · | |
| Cash Flow / Share | $-0.04 | $-0.93 | $-3.56 | · | · | · | |
| Cash / Share | $0.35 | $0.61 | $0.91 | · | · | $1.50 | |
| EPS (TTM) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | 91.3% | 229.7% | 1517.1% | · | · | · | |
| Revenue CAGR 3Y | 367.3% | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $376M | $197M | $60M | $4M | $0 | $0 | |
| Net Income TTM | $-16M | $-140M | $-262M | $-311M | $-206M | $-136M | |
| Market Cap | $3.58B | $1.64B | $313M | · | · | $1.22B | |
| Enterprise Value | $3.65B | $1.68B | $426M | · | · | · | |
| P/E | -223.4 | -12.0 | -0.9 | -2.6 | -5.0 | -7.4 | |
| P/S | 9.5 | 8.4 | 5.2 | · | · | · | |
| P/B | 18.9 | 10.4 | 3.5 | · | · | 4.5 | |
| P / Tangible Book | 20.5 | 11.1 | 3.8 | 4.5 | 3.5 | 4.5 | |
| P / Cash Flow | -636.7 | -14.6 | -1.3 | · | · | -10.8 | |
| P / FCF | -567.5 | -14.6 | -1.3 | · | · | -10.8 | |
| EV / EBITDA | -298.3 | -13.1 | -1.8 | · | · | · | |
| EV / FCF | -578.0 | -14.9 | -1.7 | · | · | · | |
| EV / Revenue | 9.7 | 8.5 | 7.1 | · | · | · | |
| Earnings Yield | -0.45% | -8.3% | -117.0% | -38.2% | -20.2% | -13.5% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $130M | $105M | $130M | $99M | $82M | $66M | $71M | $45M | $31M | $50M | $14M | $38M | $5M | $3M | $3M | $725.0K | |
| Cost of Revenue | $11M | $10M | $12M | $9M | $7M | $9M | $7M | $6M | $3M | $3M | $2M | $1M | $776.0K | $783.0K | · | · | |
| R&D Expense | $20M | $31M | $20M | $20M | $19M | $18M | $14M | $20M | $19M | $23M | $24M | $26M | $25M | $35M | $34M | $70M | |
| SG&A Expense | $82M | $74M | $79M | $62M | $69M | $64M | $58M | $59M | $58M | $55M | $49M | $48M | $46M | $43M | $37M | $35M | |
| Operating Expenses | $113M | $114M | $111M | $91M | $96M | $90M | $79M | $84M | $81M | $81M | $75M | $75M | $72M | $79M | $71M | $105M | |
| Operating Income | $16M | $-9M | $18M | $9M | $-15M | $-25M | $-8M | $-39M | $-50M | $-32M | $-61M | $-37M | $-67M | $-76M | $-68M | $-105M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $7M | · | $5M | |
| Interest Income | $2M | · | · | · | $2M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $-157.0K | $-20.0K | $-6M | $2M | $20.0K | $193.0K | $-13M | $4M | $5M | $4M | $-10M | $3M | $3M | $3M | $3M | $2M | |
| Income Tax | $136.0K | $93.0K | $470.0K | $80.0K | $342.0K | $279.0K | $323.0K | $0 | $0 | $324.0K | $90.0K | $3M | $0 | $0 | $0 | $0 | |
| Net Income | $15M | $-11M | $17M | $7M | $-16M | $-25M | $-11M | $-42M | $-52M | $-35M | $-66M | $-45M | $-71M | $-80M | $-72M | $-108M | |
| EPS (Basic) | $0.11 | $-0.09 | $0.14 | $0.06 | $-0.13 | $-0.20 | $-0.09 | $-0.33 | $-0.42 | $-0.32 | $-0.58 | $-0.73 | $-1.16 | $-1.31 | $-1.19 | $-1.89 | |
| EPS (Diluted) | $0.11 | $-0.09 | $0.14 | $0.06 | $-0.13 | $-0.20 | $-0.09 | $-0.33 | $-0.42 | $-0.32 | $-0.58 | $-0.73 | $-1.16 | $-1.31 | $-1.19 | $-1.89 | |
| Shares (Basic) | 130,522,000 | 129,365 | · | 127,623,000 | 126,997,000 | 126,037 | · | 124,302,000 | 123,481,000 | 111,048,525 | · | 61,727,278 | 61,430,620 | 61,169,089 | · | 57,091,743 | |
| Shares (Diluted) | 135,898,000 | 129,365 | · | 132,885,000 | 126,997,000 | 126,037 | · | 124,302,000 | 123,481,000 | 111,048,525 | · | 61,727,278 | 61,430,620 | 61,169,089 | · | 57,091,743 | |
| EBITDA | $16M | $-9M | · | $9M | $-15M | $-25M | · | $-39M | $-50M | · | · | $-37M | · | · | · | $-105M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $35M | $43M | $47M | $73M | $53M | $71M | $135M | $84M | $190M | · | $107M | $105M | $81M | · | $82M | |
| Receivables | $155M | $144M | $146M | $115M | $107M | $85M | $73M | $60M | $43M | $37M | · | $19M | $17M | $13M | · | $2M | |
| Inventory | $39M | $37M | $23M | $22M | $16M | $17M | $15M | $14M | $14M | $13M | · | $14M | $10M | $9M | · | $4M | |
| Prepaid Expense | $35M | $32M | $21M | $20M | $19M | $23M | $20M | $18M | $14M | $13M | · | $20M | $12M | $13M | · | $12M | |
| Current Assets | $468M | $438M | $411M | $349M | $333M | $324M | $336M | $424M | $435M | $468M | · | $282M | $309M | $368M | · | $497M | |
| PP&E (Net) | $872.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $2M | $2M | $2M | · | $2M | |
| PP&E (Gross) | · | · | $4M | · | · | · | $4M | · | · | · | · | $3M | $3M | $3M | · | $3M | |
| Accum. Depreciation | · | · | $3M | · | · | · | $3M | · | · | · | · | $2M | $2M | $1M | · | $993.0K | |
| Intangibles | $14M | $14M | $15M | $15M | $16M | $16M | $9M | $10M | $6M | $6M | · | $7M | $7M | $7M | · | $7M | |
| Other Non-current Assets | $2M | $2M | $1M | $596.0K | $596.0K | $596.0K | $596.0K | $596.0K | $595.0K | $596.0K | · | $596.0K | $596.0K | $78.0K | · | $78.0K | |
| Total Assets | $489M | $460M | $433M | $371M | $352M | $344M | $349M | $437M | $445M | $479M | · | $293M | $321M | $379M | · | $509M | |
| Accounts Payable | $7M | $18M | $13M | $6M | $15M | $25M | $14M | $19M | $8M | $13M | · | $13M | $17M | $12M | · | $9M | |
| Accrued Liabilities | $147M | $137M | $116M | $93M | $88M | $66M | $67M | $53M | $43M | $34M | · | $28M | $19M | $24M | · | $28M | |
| Current Liabilities | $160M | $163M | $130M | $100M | $104M | $91M | $81M | $172M | $51M | $47M | · | $42M | $37M | $37M | · | $37M | |
| Capital Leases | $5M | $5M | $5M | $5M | $2M | $2M | $3M | $3M | $3M | $3M | · | $4M | $4M | $4M | · | $4M | |
| Other Non-current Liabilities | $431.0K | $431.0K | $431.0K | $360.0K | $360.0K | $360.0K | $570.0K | $420.0K | $194.0K | $306.0K | · | · | · | · | · | $0 | |
| Total Liabilities | $268M | $270M | $243M | $213M | $213M | $201M | $191M | $281M | $258M | $254M | · | $246M | $240M | $240M | · | $238M | |
| Long-term Debt | $109M | $109M | $109M | $108M | $108M | $108M | $107M | $205M | $204M | $203M | · | $201M | $200M | $199M | · | $197M | |
| Total Debt | $109M | $109M | · | $108M | $108M | $108M | · | $205M | $204M | · | · | $201M | · | · | · | $197M | |
| Common Stock | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Paid-in Capital | $1.36B | $1.34B | $1.33B | $1.31B | $1.30B | $1.29B | $1.28B | $1.27B | $1.26B | $1.24B | · | $963M | $952M | $940M | · | $920M | |
| Retained Earnings | $-1.13B | $-1.15B | $-1.14B | $-1.16B | $-1.16B | $-1.15B | $-1.12B | $-1.11B | $-1.07B | $-1.02B | · | $-916M | $-871M | $-800M | · | $-648M | |
| AOCI | $-656.0K | $-514.0K | $-44.0K | $-62.0K | $-35.0K | $-140.0K | $-7.0K | $533.0K | $-294.0K | $-133.0K | · | $-184.0K | $-292.0K | $-414.0K | · | $-2M | |
| Stockholders' Equity | $221M | $190M | $189M | $158M | $139M | $143M | $158M | $157M | $186M | $225M | $89M | $47M | $81M | $140M | $210M | $271M | |
| Liabilities + Equity | $489M | $460M | $433M | $371M | $352M | $344M | $349M | $437M | $445M | $479M | · | $293M | $321M | $379M | · | $509M | |
| Shares Outstanding | 125,591,000 | 125,042,000 | 123,332,672 | 120,288,146 | 119,797,738 | 119,137,785 | 117,848,033 | 116,998,829 | 116,480,267 | 115,505,437 | · | 61,858,044 | 61,630,018 | 61,357,932 | · | 60,908,641 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $13M | $11M | $10M | $10M | $10M | $10M | $9M | $10M | $13M | $10M | $9M | $10M | $11M | $9M | $9M | $9M | |
| Amort. of Intangibles | $563.0K | $562.0K | $563.0K | $562.0K | $563.0K | $3M | $313.0K | $1M | $200.0K | $188.0K | $-188M | $188M | $200.0K | $188.0K | $187.0K | $125.0K | |
| Operating Cash Flow | $13M | $2M | $26M | $-2M | $324.0K | $-30M | $-748.0K | $-35M | $-45M | $-32M | $-56M | $-44M | $-66M | $-80M | $-71M | $-68M | |
| CapEx | $158.0K | $0 | $0 | $0 | $78.0K | $608.0K | $0 | $143.0K | $0 | $0 | $6.0K | $64.0K | $276.0K | $82.0K | $123.0K | $6.0K | |
| Investing Cash Flow | $-15M | $-11M | $-34M | $-25M | $17M | $12M | $35M | $85M | $-62M | $-29M | $-62M | $46M | $89M | $108M | $42M | $-197M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Stock Issued | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $162M | $0 | $0 | $0 | $0 | $0 | $162M | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $2M | $1M | $4M | $1M | $1M | $395.0K | $-97M | $394.0K | $1M | $162M | $99M | $867.0K | $1M | $100.0K | $962.0K | $285M | |
| Net Change in Cash | $-641.0K | $-8M | $-4M | $-26M | $19M | $-18M | $-64M | $51M | $-106M | $101M | $-19M | $2M | $24M | $27M | $-28M | $20M | |
| Free Cash Flow | · | $2M | · | · | · | $-31M | · | · | · | · | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | -8.6% | · | 8.6% | -17.9% | -37.2% | · | -87.3% | -162.3% | · | · | -96.8% | · | · | · | -14448.0% | |
| Net Margin | 11.6% | -10.7% | · | 7.5% | -19.5% | -38.1% | · | -92.8% | -169.6% | · | · | -117.5% | · | · | · | -14856.4% | |
| EBITDA Margin | 12.7% | -8.6% | · | 8.6% | -17.9% | -37.2% | · | -87.3% | -162.3% | · | · | -96.8% | · | · | · | -14448.0% | |
| ROA | 3.6% | -2.8% | · | 1.8% | -4.0% | -6.1% | · | -11.4% | -13.7% | · | · | -11.2% | · | · | · | -24.0% | |
| ROE | 8.3% | -6.8% | · | 4.7% | -9.8% | -13.6% | · | -40.8% | -39.2% | · | · | -28.2% | · | · | · | -34.0% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.9 | 2.7 | · | 3.5 | 3.2 | 3.6 | · | 2.5 | 8.5 | · | · | 6.7 | · | · | · | 13.4 | |
| Quick Ratio | 1.2 | 1.1 | · | 1.6 | 1.7 | 1.5 | · | 1.1 | 2.5 | · | · | 3.0 | · | · | · | 2.3 | |
| Debt / Equity | 0.5 | 0.6 | · | 0.7 | 0.8 | 0.8 | · | 1.3 | 1.1 | · | · | 4.3 | · | · | · | 0.7 | |
| LT Debt / Equity | 0.5 | 0.5 | · | 0.7 | 0.8 | 0.8 | · | 0.7 | 1.1 | · | · | 4.3 | · | · | · | 0.7 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -4.9 | · | · | · | -21.4 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.1 | 0.1 | · | · | 0.1 | · | · | · | 0.0 | |
| Inventory Turnover | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.6 | · | 0.4 | 0.3 | · | · | · | · | · | · | · | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.1 | 1.1 | 1.1 | · | 1.1 | 1.0 | · | · | 3.5 | · | · | · | 0.6 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.76 | $1.52 | · | $1.31 | $1.16 | $1.20 | · | $1.34 | $1.60 | · | · | $0.76 | · | · | · | $4.45 | |
| Revenue / Share | $0.96 | $814.73 | · | $0.75 | $0.64 | $0.52 | · | $0.36 | $0.25 | · | · | $0.62 | · | · | · | $0.01 | |
| Cash Flow / Share | · | $17.31 | · | · | · | $-0.24 | · | · | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.27 | $0.28 | · | $0.39 | $0.61 | $0.45 | · | $1.15 | $0.72 | · | · | $1.74 | · | · | · | $1.34 | |
| EPS (TTM) | $0.22 | $-0.02 | · | $-0.36 | $-0.75 | $-1.04 | · | $-1.65 | $-2.05 | $-3.52 | · | $-4.39 | $-5.67 | $-5.78 | · | $-5.91 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $464M | $416M | · | $318M | $263M | $213M | · | $139M | $132M | $96M | · | $49M | $9M | $4M | · | $725.0K | |
| Net Income TTM | $29M | $-2M | · | $-44M | $-93M | $-130M | · | $-196M | $-199M | $-231M | · | $-268M | $-326M | $-320M | · | $-311M | |
| Market Cap | $3.29B | $2.95B | · | $2.27B | $1.68B | $1.86B | · | $1.09B | $1.08B | · | · | $328M | · | · | · | $1.16B | |
| Enterprise Value | $3.37B | $3.02B | · | $2.33B | $1.71B | $1.92B | · | $1.16B | $1.20B | · | · | $422M | · | · | · | $1.28B | |
| P/E | 119.2 | -1178.0 | · | -52.4 | -18.7 | -15.0 | · | -5.6 | -4.5 | -2.8 | · | -1.2 | -1.7 | -1.9 | · | -3.2 | |
| P/S | 7.1 | 7.1 | · | 7.1 | 6.4 | 8.8 | · | 7.8 | 8.2 | · | · | 6.7 | · | · | · | 1605.5 | |
| P/B | 14.9 | 15.5 | · | 14.3 | 12.1 | 13.1 | · | 6.9 | 5.8 | · | · | 7.0 | · | · | · | 4.3 | |
| P / Tangible Book | 15.9 | 16.8 | · | 15.9 | 13.7 | 14.8 | · | 7.4 | 6.0 | 5.2 | · | 8.2 | 8.0 | 5.1 | · | 4.4 | |
| P / Cash Flow | · | 1315.8 | · | · | · | -61.3 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 7.3 | 7.3 | · | 7.3 | 6.5 | 9.0 | · | 8.3 | 9.1 | · | · | 8.6 | · | · | · | 1764.4 | |
| Earnings Yield | 0.84% | -0.08% | · | -1.9% | -5.3% | -6.7% | · | -17.7% | -22.0% | -35.5% | · | -82.7% | -59.5% | -52.5% | · | -30.9% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $376M | $197M | $60M | $4M | $0 |
| Faaliyet Kâr Marjı % | -3.2% | -65.3% | -404.5% | · | · |
| Net Gelir | $-16M | $-140M | $-262M | $-311M | $-206M |
| Seyreltilmiş Hisse Başı Kâr | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.6 | 0.7 | 2.3 | · | · |
| Cari Oran | 3.2 | 4.1 | 7.1 | · | · |
| Cari Oran | 1.5 | 1.8 | 2.4 | · | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-6M | $-112M | $-247M | · | · |
Kurumsal Sahipler (13F) 289 dosya · $3.6B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
289
Tutulan Değer
$3.6B
Yeni pozisyonlar
39
Çıkan pozisyonlar
33
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 39 (-4 önceki Ç'ye göre) | 33 (-9 önceki Ç'ye göre) | 93 (-10 önceki Ç'ye göre) | 101 (+13 önceki Ç'ye göre) | -1.9M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | $326.098.140 | 12.437.000 | 8,97% | Hisse senetleri |
| BlackRock, Inc. | $276.502.120 | 10.545.466 | 7,61% | Hisse senetleri |
| Frazier Life Sciences Management, L.P. | $258.909.678 | 9.874.511 | 7,12% | Hisse senetleri |
| Rubric Capital Management LP | $216.880.749 | 8.271.577 | 5,97% | Hisse senetleri |
| VANGUARD GROUP INC | $210.654.301 | 7.253.936 | 5,80% | Hisse senetleri |
| Polar Capital Holdings Plc | $173.234.098 | 6.606.945 | 4,77% | Hisse senetleri |
| STATE STREET CORP | $152.674.865 | 5.822.840 | 4,20% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $130.805.182 | 4.988.756 | 3,60% | Hisse senetleri |
| MORGAN STANLEY | $116.705.607 | 4.451.014 | 3,21% | Hisse senetleri |
| JENNISON ASSOCIATES LLC | $110.623.703 | 4.219.058 | 3,04% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $103.558.748 | 3.949.609 | 2,85% | Hisse senetleri |
| UBS Group AG | $87.391.654 | 3.333.015 | 2,40% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $78.330.441 | 2.987.431 | 2,16% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $78.214.092 | 2.982.446 | 2,15% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $63.688.511 | 2.429.005 | 1,75% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $53.541.240 | 2.042.000 | 1,47% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $50.630.354 | 1.930.982 | 1,39% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $50.474.363 | 1.925.031 | 1,39% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $43.744.582 | 1.668.367 | 1,20% | Hisse senetleri |
| JANUS HENDERSON GROUP PLC | $43.684.303 | 1.854.566 | 1,20% | Hisse senetleri |
| OBERWEIS ASSET MANAGEMENT INC/ | $35.998.513 | 1.372.941 | 0,99% | Hisse senetleri |
| GILDER GAGNON HOWE & CO LLC | $34.432.392 | 1.313.211 | 0,95% | Hisse senetleri |
| Pivotal bioVenture Partners Investment Advisor LLC | $33.175.720 | 1.265.283 | 0,91% | Hisse senetleri |
| BAMCO INC /NY/ | $32.856.806 | 1.253.120 | 0,90% | Hisse senetleri |
| CITADEL ADVISORS LLC | $30.415.567 | 1.160.014 | 0,84% | Hisse senetleri |
| FEDERATED HERMES, INC. | $29.487.772 | 1.124.629 | 0,81% | Hisse senetleri |
| Perpetual Ltd | $29.095.206 | 1.109.657 | 0,80% | Hisse senetleri |
| Aberdeen Group plc | $28.800.336 | 1.098.411 | 0,79% | Hisse senetleri |
| Jones Hill Capital LP | $28.571.960 | 1.089.701 | 0,79% | Hisse senetleri |
| NORTHERN TRUST CORP | $27.755.837 | 1.058.575 | 0,76% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $27.555.489 | 1.050.934 | 0,76% | Hisse senetleri |
| Ensign Peak Advisors, Inc | $25.552.281 | 974.534 | 0,70% | Hisse senetleri |
| Candriam S.C.A. | $24.880.817 | 949.839 | 0,68% | Hisse senetleri |
| Driehaus Capital Management LLC | $23.032.330 | 878.426 | 0,63% | Hisse senetleri |
| Nuveen, LLC | $21.874.324 | 834.261 | 0,60% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $21.372.918 | 815.138 | 0,59% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21.284.137 | 811.752 | 0,59% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $17.406.855 | 663.877 | 0,48% | Hisse senetleri |
| FISHMAN JAY A LTD/MI | $15.601.031 | 595.005 | 0,43% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $14.789.968 | 564.072 | 0,41% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $14.349.629 | 547.278 | 0,39% | Hisse senetleri |
| Squarepoint Ops LLC | $14.099.726 | 537.747 | 0,39% | Hisse senetleri |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | $13.110.000 | 500.000 | 0,36% | Hisse senetleri |
| Nearwater Capital Markets, Ltd | $12.761.274 | 486.700 | 0,35% | Hisse senetleri |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12.218.520 | 466.000 | 0,34% | Hisse senetleri |
| MARSHALL WACE, LLP | $11.716.827 | 446.866 | 0,32% | Hisse senetleri |
| Privium Fund Management B.V. | $10.471.403 | 399.367 | 0,29% | Hisse senetleri |
| NORGES BANK | $10.286.106 | 392.300 | 0,28% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $10.033.923 | 382.682 | 0,28% | Hisse senetleri |
| Patient Square Capital LP | $9.701.400 | 370.000 | 0,27% | Hisse senetleri |
Aktivistler ve %5+ sahipler 3 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., Frazier Life Sciences XII, L.P., FHMLS XII, L.P., FHMLS XII, L.L.C., James N. Topper, Patrick J. Heron ×8 başvurular | 20 Ağustos 2025 | 7,50% | Değişiklik | Pasif yatırım | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, OrbiMed Capital LLC ×7 başvurular | 26 Ağustos 2022 | · | İlk başvuru | · | SEC |
| Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP ×4 başvurular | 08 Ağustos 2022 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 26 içeriden öğrenenler · 12 yöneticiler · 14 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Todd Franklin Watanabe | Reporting Person's title: President and Chief Executive Officer | 03 Ağustos 2026 S | 717.203 | 0 | 13 | $-5.324.269 |
| Latha Vairavan | SVP Chief Financial Officer | 11 Mayıs 2026 S | 85.978 | 0 | 6 | $-148.496 |
| David Joseph Topper | Chief Financial Officer | 02 Nisan 2025 S | 182.774 | 0 | 0 | $0 |
| John W Smither | Chief Financial Officer | 13 Şubat 2024 D | 11.365 | 0 | 0 | $0 |
| Scott L Burrows | Chief Financial Officer | 06 Mart 2023 S | 59.115 | 0 | 0 | $0 |
| Masaru Matsuda | Reporting Person's title: EVP, Chief Legal Officer | 16 Eylül 2026 S | 112.508 | 0 | 18 | $-2.207.960 |
| Patrick Burnett | Reporting Person's title: EVP, Chief Medical Officer | 19 Ağustos 2026 S | 117.592 | 0 | 18 | $-2.019.340 |
| Larry Todd Edwards | Reporting Person's title: EVP, Chief Commercial Officer | 27 Şubat 2026 A | 175.178 | 0 | 6 | $-968.374 |
| Matthew Richard Moore | SVP and Chief Business Officer | 02 Mayıs 2024 S | 145.505 | 0 | 0 | $0 |
| Kenneth A. Lock | Chief Commercial Officer | 06 Mart 2023 S | 63.429 | 0 | 0 | $0 |
| Patricia A. Turney | SVP, Operations | 06 Mart 2023 S | 62.862 | 0 | 0 | $0 |
| David W Osborne | Chief Technical Officer | 06 Mart 2023 S | 268.854 | 0 | 0 | $0 |
| Howard G. Welgus | Yönetim kurulu üyesi | 15 Eylül 2026 M | 35.841 | 0 | 14 | $-2.425.410 |
| Terrie Curran | Yönetim kurulu üyesi | 27 Ağustos 2026 M | 23.526 | 0 | 3 | $-984.061 |
| Christopher Peetz | Yönetim kurulu üyesi | 15 Temmuz 2026 A | 4.315 | 0 | 0 | $0 |
| Sue-Jean Lin | Yönetim kurulu üyesi | 15 Haziran 2026 S | 27.567 | 0 | 2 | $-898.455 |
| Neha Krishnamohan | Yönetim kurulu üyesi | 05 Haziran 2026 A | 27.901 | 0 | 2 | $-939.510 |
| Amit Munshi | Yönetim kurulu üyesi | 05 Haziran 2026 A | 9.799 | 0 | 0 | $0 |
| Halley E Gilbert | Yönetim kurulu üyesi | 05 Haziran 2026 A | 27.901 | 0 | 1 | $-455.457 |
| Keith R Leonard | Yönetim kurulu üyesi | 05 Haziran 2026 A | 27.901 | 0 | 1 | $-997.116 |
| Patrick J. Heron | Yönetim kurulu üyesi | 05 Haziran 2026 A | 32.213 | 0 | 0 | $0 |
| Bhaskar Chaudhuri | Yönetim kurulu üyesi | 12 Haziran 2025 A | 867.826 | 0 | 0 | $0 |
| Joseph L Turner | Yönetim kurulu üyesi | 01 Haziran 2022 A | 4.312 | 0 | 0 | $0 |
| Jonathan Silverstein | Yönetim kurulu üyesi | 02 Ekim 2020 P | 902.286 | 0 | 0 | $0 |
| Daniel Estes | Yönetim kurulu üyesi | 27 Şubat 2020 A | · | 0 | 0 | $0 |
| Ricky Sun | · | 09 Haziran 2021 A | · | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 37 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| RZG · Invesco Exchange-Traded Fund Trust | 1,71% | 77.200 SH | 01 Ekim 2026 | Günlük |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,63% | 109.981 SH | 01 Ekim 2026 | Günlük |
| BBP · ETFis Series Trust I | 1,52% | 55.666 NS | 31 Temmuz 2026 | N-PORT |
| GURU · Global X Funds | 1,46% | 33.313 NS | 31 Temmuz 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,43% | 199.300 SH | 01 Ekim 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,54% | 98.745 NS | 31 Temmuz 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,42% | 64.059 SH | 01 Ekim 2026 | Günlük |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,41% | 197.027 NS | 31 Temmuz 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,22% | 107.502 NS | 31 Temmuz 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,22% | 8.879 SH | 01 Ekim 2026 | Günlük |
| IBB · iShares Trust | 0,19% | 842.985 SH | 11 Eylül 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,18% | 122.691 SH | 19 Ağustos 2026 | Günlük |
| IWO · iShares Trust | 0,18% | 1.074.467 SH | 11 Eylül 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,15% | 1.349 NS | 31 Temmuz 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,13% | 66.540 NS | 31 Temmuz 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,12% | 3.883 NS | 31 Temmuz 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,11% | 29.355 NS | 31 Temmuz 2026 | N-PORT |
| RSSL · Global X Funds | 0,10% | 54.786 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,09% | 658.480 SH | 19 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,09% | 2.915.298 SH | 11 Eylül 2026 | Günlük |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 17.847 NS | 31 Temmuz 2026 | N-PORT |
| ISCG · iShares Trust | 0,08% | 34.084 SH | 11 Eylül 2026 | Günlük |
| ESML · iShares Trust | 0,07% | 88.662 SH | 11 Eylül 2026 | Günlük |
| VFMO · VANGUARD WELLINGTON FUND | 0,07% | 55.080 SH | 19 Ağustos 2026 | Günlük |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,06% | 5.568 SH | 01 Ekim 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,05% | 46.067 SH | 01 Ekim 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 53.372 NS | 31 Temmuz 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,04% | 335.913 SH | 19 Ağustos 2026 | Günlük |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,03% | 24.646 SH | 01 Ekim 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 1.307.970 SH | 19 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,02% | 6.362 SH | 11 Eylül 2026 | Günlük |
| TILT · FlexShares Trust | 0,00% | 3.204 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 152.928 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 31.652 SH | 10 Eylül 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 3.565.928 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.521 SH | 19 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 4.781 SH | 11 Eylül 2026 | Günlük |
ARQT Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 14 analist
AL
Medyan hedef
$38.00
+51,0%
4 28,6%
Güçlü Al
8 57,1%
Al
2 14,3%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
7 analist · 2026-10-01Ortalama hedef $37.00 +47,1%
← Tüm hedeflerin altında
Mevcut fiyat $25.16
Düşük$34.00
Ortalama$37.00
Yüksek$40.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| ARQT | $3.58B | -223.4 | 91.3% | -4.3% | -9.8% | · |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | · |
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | · |
| DNLI | $2.58B | -5.6 | 204.7% | · | -50.2% | · |
| RCUS | $2.99B | -7.2 | -4.3% | -142.9% | -59.8% | · |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | · |
| PURR | $1.58B | 2.5 | · | 3229.8% | 24.8% | · |
| DYN | $3.23B | -5.6 | · | · | -57.8% | · |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 5, 2026